All kinds of INSTI medications

PreclinicalSmall molecule

All kinds of INSTI medications is one of 41 small molecule programs targeting HIV-1 infection. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HIV-1 InfectionActive, not recruiting

HIV-1 InfectionPreclinical

Active, not recruiting

Competition

Competitive Landscape

165 competitors in HIV-1 Infection

#DrugCompanyPhaseTrials

Sunlenca

Gilead

Phase 3

5 2

Norvir

AbbVie

Phase 3

3 3

Tivicay

GSK

Phase 3

2 4

Biktarvy

Gilead

Phase 3

1 5

Invirase

Roche

Phase 3

1 6

FTC/TDF

Gilead

Phase 3

2 7

F/TAF

Gilead

Phase 3

1 8

F/TDF

Gilead

Phase 3

1 9

Focetria

CChiltern Pesquisa Clinica Ltda

Phase 3

1 10

Entyvio

Takeda

Phase 2

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Not yet recruiting

HIV-1 Infection

NCT07080138

Clinical

Trials by Indication[1]

HIV-1 infection1 trial

Research on the Psychological Status of Patients With HIV-1 Infection

Not yet recruiting·SShanxi Bethune Hospital··NCT07080138·500 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for All kinds of INSTI medications. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — All kinds of INSTI medications compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for All kinds of INSTI medications. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shanxi Bethune Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: SShanxi Bethune Hospital

All kinds of INSTI medications

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

HIV-1 infection1 trial

References

Drug Info

Quick Facts

Related News